Disease | encephalopathy |
Comorbidity | C0020541|portal hypertension |
Sentences | 3 |
PubMedID- 20482828 | Therefore, we suggest that patients with liver cirrhosis and portal hypertension are at risk of developing clinically relevant encephalopathy when angiotensin-converting enzyme inhibitor and angiotensin ii receptor blocker combination therapy is administered, thus indicating the need for a careful clinical follow-up. |
PubMedID- 26203291 | In this review, we address four major areas of cirrhosis management: outpatient management of portal hypertension with decompensation, hepatic encephalopathy, hepatorenal syndrome, and bleeding/coagulation issues. |
PubMedID- 23454902 | Cirrhosis results from repeated hepatocellular injury over time, leading to portal hypertension and the development of ascites, hepatic encephalopathy, and varices. |
Page: 1